Parkinson Disease
DOI:
https://doi.org/10.59841/an-najat.v1i4.556Keywords:
Parkinson DiseaseAbstract
Parkinson's disease is a disorder of brain function caused by the degeneration process of the basal ganglia in the substantia nigra pars compacta (SNc) cells and is characterized by characteristics such as tremors at rest, muscle and joint stiffness (rigidity), slowness of movement and speech (bradykinesia) and instability. upright position (postural instability). There is no medicine or treatment that can change Parkinson's Disease. The most effective symptomatic treatment is levodopa, which has better effectiveness on quality of life in Parkinson's Disease than other therapies. Motor fluctuations and dyskinesias later in the course of the disease may be improved with additional treatment. There are 10% of patients per year with intractable motor fluctuations who undergo further therapy, including deep brain stimulation surgery. The importance of multidisciplinary care has been proven to better manage non-motor symptoms in Parkinson's Disease.
References
Acidic GF (2021) Research paper: paeonol protection against intrastri- atal 6-hydroxydopamine rat model of Parkinson’s disease. Basic Clin Neurosci 12:43–56.
Adam H, Gopinath SCB, Arshad MKM et al (2021) Distinguishing normal and aggregated alpha-synuclein interaction on gold nanorod incorporated zinc oxide nanocomposite by electrochemi- cal technique. Int J Biol Macromol 171:217–224. https://doi.org/ 10.1016/j.ijbiomac.2021.01.014
Aghili Z, Nasirizadeh N, Divsalar A et al (2018) A highly sensitive miR-195 nanobiosensor for early detection of Parkinson’s dis- ease. Artif Cells Nanomed Biotechnol 46:32–40. https://doi.org/ 10.1080/21691401.2017.1411930
Ball N, Teo WP, Chandra S, Chapman J (2019) Parkinson’s disease and the environment. Front Neurol. https://doi.org/10.3389/fneur. 2019.00218
Banigo AT, Azeez TO, Ejeta KO et al (2020) Nanobiosensors: applica- tions in biomedical technology. IOP Conf Ser. https://doi.org/10. 1088/1757-899X/805/1/012028
Barrett MJ, Sargent L, Nawaz H et al (2021) Antimuscarinic anticho- linergic medications in Parkinson disease: to prescribe or depre- scribe? Movement Disord Clin Pract 8:1181–1188. https://doi. org/10.1002/mdc3.13347
Carbone F, Djamshidian A, Seppi K, Poewe W (2019) Apomorphine for Parkinson’s disease: efficacy and safety of current and new formulations. CNS Drugs 33:905–918. https://doi.org/10.1007/ s40263-019-00661-z
Chang KH, Chen CM (2020) The role of oxidative stress in Parkin- son’s disease. Antioxidants 9:1–32. https://doi.org/10.3390/antio x9070597
Dahbour SS, Al Murr MJ, Oweis LH et al (2022) Non-motor manifesta- tion of Parkinson’s disease: a cross-sectional study in a teaching hospital in Jordan. Egypt J Neurol Psychiatry Neurosurg. https:// doi.org/10.1186/s41983-022-00559-6
Day JO, Mullin S (2021) The genetics of parkinson’s disease and impli- cations for clinical practice. Genes. https://doi.org/10.3390/genes 12071006
DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 14:32
Dixit S, Bohre K, Singh Y et al (2023) A Comprehensive review on AI-enabled models for Parkinson’s disease diagnosis. Electron- ics 12(4):783
Erkmen C, Selcuk O, Unal DN et al (2022) Layer-by-layer modification strategies for electrochemical detection of biomarkers. Biosens Bioelectron 12:100270. https://doi.org/10.1016/j.biosx.2022.100270
Fruncillo S, Su X, Liu H, Wong LS (2021) Lithographic processes for the scalable fabrication of micro- and nano-structures for bio- chips and biosensors. ACS Sens. https://doi.org/10.1021/acsse nsors.0c02704
Gajdosova V, Lorencova L, Kasak P, Tkac J (2020) Electrochemical nanobiosensors for detection of breast cancer biomarkers. Sen- sors (switzerland) 20:1–37. https://doi.org/10.3390/s20144022
Hyun J, Young K, Suh J et al (2021) Technological advances in elec- trochemical biosensors for the detection of disease biomark- ers. Biomed Eng Lett 11:309–334. https://doi.org/10.1007/ s13534-021-00204-w
Ionescu RE (2022) Use of cysteamine and glutaraldehyde chemicals for robust functionalization of substrates with protein biomark- ers—an overview on the construction of biosensors with different transductions. Biosensors. https://doi.org/10.3390/bios12080581 Ivanidze J, Skafida M, Pandya S et al (2020) Molecular imaging of striatal dopaminergic neuronal loss and the neurovascular unit
in Parkinson disease. Front Neurosci 14:1–9. https://doi.org/10. 3389/fnins.2020.528809
Jang SJ, Lee CS, Kim TH (2020) α-Synuclein oligomer detection with aptamer switch on reduced graphene oxide electrode. Nanoma- terials 10:1–11. https://doi.org/10.3390/nano10050832
Rai SN, Zahra W, Sen SS et al (2019) Anti-inflammatory activ- ity of ursolic acid in MPTP-induced parkinsonian mouse model. Neurotox Res 36:452–462. https://doi.org/10.1007/ s12640-019-00038-6
Rivero-ríos P, Romo-lozano M, Fasiczka R, Naaldijk Y (2020) LRRK2- related Parkinson’s disease due to altered endolysosomal biology with variable lewy body pathology: a hypothesis. Front Neurosci 14:1–16.
https://doi.org/10.3389/fnins.2020.00556
Russillo MC, Andreozzi V, Erro R et al (2022) Sex differences in Par- kinson’ s disease: from bench to bedside. Brain Sci 12(7):917
Selvaraj S, Piramanayagam S (2019) Impact of gene mutation in the development of Parkinson’s disease. Genes Dis 6(2):120–128.
https://doi.org/10.1016/j.gendis.2019.01.004
Shabani L, Abbasi M, Azarnew Z et al (2023) Neuro-nanotechnology: diagnostic and therapeutic nano-based strategies in applied neu- roscience. Biomed Eng Online 22:1–41. https://doi.org/10.1186/ s12938-022-01062-y
Sharma P, Pandey V, Sharma MMM et al (2021) A review on biosen- sors and nanosensors application in agroecosystems. Nanoscale Res Lett. https://doi.org/10.1186/s11671-021-03593-0
Shi M, Chai Y, Zhang J, Chen X (2022) Endoplasmic reticulum stress- associated neuronal death and innate immune response in neu- rological diseases. Front Immunol 12:1–26. https://doi.org/10. 3389/fimmu.2021.794580
Tolosa E, Garrido A, Scholz SW et al (2022) Challenges in the diag- nosis of Parkinson’s disease. Lancet Neurol 20:385–397. https:// doi.org/10.1016/S1474-4422(21)00030-2.Challenges
Tran J, Anastacio H, Bardy C (2020) Genetic predispositions of Parkin- son’s disease revealed in patient-derived brain cells. NPJ Parkin- son’s Dis. https://doi.org/10.1038/s41531-020-0110-8
Verger A, Grimaldi S, Ribeiro MJ et al (2021) Single photon emission computed tomography/positron emission tomography molecular imaging for Parkinsonism: a fast-developing field. Ann Neurol 90:711–719.
